

Board regular items and responsibilities

<p>Chief Executive's report</p> <ul style="list-style-type: none"> Operational update from the business divisions New greenfield opportunities and partnerships Issues arising across the Group 	<p>Committee reports</p> <ul style="list-style-type: none"> Committee Chair updates on business of the Committee Discussion of recommended actions Delegation of issues to management 	<p>Investors and markets</p> <ul style="list-style-type: none"> Capital and pharmaceutical markets updates Market consensus information Investor relations annual review
<p>Legal</p> <ul style="list-style-type: none"> Regulatory issues Litigation developments Legal compliance updates Legal and regulatory updates 	<p>Strategic</p> <ul style="list-style-type: none"> Business environment updates Pharmaceutical market strategy Specific M&A opportunities 	<p>Risk</p> <ul style="list-style-type: none"> Risk appetite Principal risks Deep dive assessments Management framework
<p>Finance</p> <ul style="list-style-type: none"> Financial reporting Flash sales Forecasting Budgeting 	<p>Governance</p> <ul style="list-style-type: none"> Board process enhancements UK and listed environment developments Annual governance review 	<p>Training</p> <ul style="list-style-type: none"> Company specific training Professional adviser opportunities Bespoke training programmes